ASND
Ascendis Pharma AS
227.80$
-0.1%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -41.9% | -43.3% | -66.8% | +591.6% | +26.4% | -48.0% | +11.9% | +557.9% | +421.2% | +36.3% | +90.2% | |
| – | +94,012,553,396.7% | -100.0% | +15,061,237.1% | -100.0% | – | – | – | +244.5% | +265.8% | -0.3% | +133.1% | |
| – | -41.9% | -43.3% | -66.8% | +591.6% | +26.4% | -48.0% | -38.8% | +817.4% | +469.5% | +43.7% | +84.3% | |
| – | +105.7% | +62.9% | +50.8% | +40.9% | +36.6% | +36.2% | +13.4% | +28.3% | +8.9% | -25.7% | -7.7% | |
| – | +50.1% | +22.2% | +17.2% | +85.9% | +93.5% | +58.2% | +108.9% | +34.8% | +19.9% | +10.0% | +57.5% | |
| – | +92.3% | +55.2% | +45.8% | +46.2% | +45.2% | +40.6% | +35.1% | +31.8% | +12.8% | -11.8% | +20.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -62.5% | -16.7% | +1,840.0% | +30.9% | +861.4% | +57.1% | +103.9% | +684.5% | +43.6% | +48.7% | +18.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | +35.8% | -33.7% | +205.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.